Please assess the completion status of the following clinical trial:

Trial Title: An Observational Study to Predict the Response of Erythropoietin Treatment in Participants With Cancer Related Anemia Receiving Chemotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participants with non-hematologic malignancy (cancer or other progressively enlarging and spreading tumor, usually fatal if not successfully treated)~* Participants with life expectancy of at least 6 months based on the Investigator's clinical judgment~* Participants receiving chemotherapy~* Participants having indication and planning to receiving erythropoietin (dosage and regimen should comply with Thai FDA approval package insert)~* Participants who have given consent form~Exclusion Criteria:~* Participants with anemia due to other factors (i.e., iron, B12 or folate deficiencies, hemolysis \[breakdown in red blood cells\], gastrointestinal bleeding, or any active bleeding)~* Participants with previous history of erythropoietin treatment~* Participants who have received blood transfusion within 1 month before starting erythropoietin therapy~* Pregnant or breast-feeding female participants

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Participants with cancer related anemia (Type: None): Participants with cancer related anemia receiving chemotherapy will be observed for response to erythropoietin treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).